Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer

Gastric Cancer

Volumn 7, Issue 4, 2004, Pages 240-245

  Popiela, Tadeusz ^a   Kulig, Jan ^a   Czupryna, Antoni ^a   Szczepanik, Antoni M ^a   Zembala, Marek ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

BCG; Chemotherapy; FAM; Gastric cancer; Immunochemotherapy

Indexed keywords

BCG VACCINE; DIPYRONE; DOXORUBICIN; FLUOROURACIL; MITOMYCIN C; PARACETAMOL;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; GASTRECTOMY; HUMAN; INFLAMMATION; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH CANCER; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; FLUOROURACIL; GASTRECTOMY; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MITOMYCIN; MYCOBACTERIUM BOVIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 12444256374     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-004-0299-y     Document Type: Article

References (28)

1. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment (Review). Ann Oncol 2003;14(Suppl 2):31-6.
2. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
3. Grau JJ, Martin M, Fuster J, Pera M, Garcia-Valdecasas JC, Bombi JA, et al. Impact of adjuvant chemotherapy in the long-term outcome of patients with resected gastric cancer. J Surg Oncol 2003;82:234-40.
4. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 2003;21:2282-7.
5. Macdonald JS, Schein PS, Wooley PV. 5 Fluorouracil, doxorubicin, mitomycin C (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980;93:533-6.
6. + T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997;89:3700-7.
7. Ochiai T, Sato H, Hayashi R, Asano T, Sato H, Yamamura Y. Postoperative adjuvant immunotherapy of gastric cancer with BCG cell wall skeleton. Cancer Immunol Immunother 1983;14:167-71.
8. Lamm DL. Optimal BCG treatment of superficial bladder cancer as defined by American trials. Eur Urol 1992;21:12-6.
9. Popiela T, Zembala M, Oszacki J, Jȩdrychowski W. A follow-up study on chemoimmunotherapy (5-fluorouracil and BCG) in advanced gastric cancer. Cancer Immunol Immunother 1982;13:182-4.
10. Fielding JW, Roginski C, Ellis DJ, Jones BG, Powell J, Waterhouse JA, et al. Clinicopathological staging of gastric cancer. Br J Surg 1984;71:677-80.
11. Hermanek P, Sobin LH. UICC: TNM Classification of malignant tumours. 5th ed. Berlin Heidelberg New York Tokyo: Springer: 1997. pp. 24-5.
12. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987;11:418-25.
13. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at histoclinical classification. Acta Pathol Microbiol Scand 1965;64:31-42.
14. Green S, Heiss GR. Southwest Oncology Group Standard Response Criteria, end point definition, and toxicity criteria. Invest New Drugs 1992;10:239-53.
15. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomised clinical trial requiring prolonged observation of each patient. II Analysis and examples. Br J Cancer 1977;35:1-39.
16. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 1994;343:1122-6.
17. Lise M, Nitti D, Marchet A, Sahmoud T, Buyse M, Duez N, et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol 1995;13:2757-63.
18. Macdonald JS, Fleming TR, Peterson RF, Berenberf JL, McClure S, Chapman RA, et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: Southwest Oncology Group study. Ann Surg Oncol 1995;2:488-94.
19. Zembala M, Czupryna A, Wiȩckiewicz J, Jasiński M, Pryjma J, Ruggiero I. Tumour-cell induced production of tumour necrosis factor by monocytes of gastric cancer patients receiving BCG immunotherapy. Cancer Immunol Immunother 1993;36:127-32.
20. Bajetta E, Di Bartolomeo M, Carnaghi C, Buzzoni R, Mariani L, Gebbia V, et al. FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study. Br J Cancer 1998;77:1149-54.
21. MathÉ G. Systemic active immunotherapy is shifting from middle ages to renaissance period. I. The multiplication of randomized trials showing significant effect of active immunotherapy on residual minimal disease. Cancer Immunol Immunother 1978;35:149-52.
22. Kondo T, Sakamoto J, Nakazato H. Alternating immunochemotherapy of advanced gastric carcinoma: a randomized comparison of carbazilquinone and PSK to carbazilquinone in patients with curative gastric resection. Biotherapy 1991;3:287-95.
23. Maehara Y, Okuyama T, Kakeji Y, Baba H, Furusawa M, Sugimachi K. Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg 1994;169:36-40.
24. Buzdar AU, Blumenschein GR, Smith TR. Adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide, with or without BCG and with or without irradiation in operable breast cancer. Cancer 1984;53:384-9.
25. Jackson AM, James K. Understanding the most successful immunotherapy for cancer. Immunologist 1994;2:208-15.
26. Pryor K, Goddard J, Golstein D, Stricker P, Russel P, Golovsky D. BCG enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer 1995;71:801-07.
27. Fujimoto T, Duda RB, Szilvasi A, Chen X, Mai M, O'Donnell MA. Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. J Immunol 1997;158:5619-26.
28. Karcz D, Popiela T, Szczepanik AM, Czupryna A, Szymańska B, Siedlar M, et al. Preoperative endoscopic intratumour application of TNF alpha in patients with locally advanced resectable gastric cancer. Endoscopy 1994;26:369-70.